GLPG
Price:
$27.98
Market Cap:
$1.51B
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Industry
Biotechnology
IPO Date
2012-02-27
Stock Exchange
NASDAQ
Ticker
GLPG
According to Galapagos N.V.’s latest financial reports and current stock price. The company's current PE Ratio is 3.21. This represents a change of -46.38% compared to the average of 5.99 of the last 4 quarters.
The mean historical PE Ratio of Galapagos N.V. over the last ten years is 5.71. The current 3.21 PE Ratio has changed 5.52% with respect to the historical average. Over the past ten years (40 quarters), GLPG's PE Ratio was at its highest in in the March 2026 quarter at 29.49. The PE Ratio was at its lowest in in the June 2025 quarter at -3.71.
Average
5.71
Median
5.71
Minimum
5.71
Maximum
5.71
Discovering the peaks and valleys of Galapagos N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 5.71
Minimum Annual Increase = 0%
Minimum Annual PE Ratio = 5.71
| Year | PE Ratio | Change |
|---|
The current PE Ratio of Galapagos N.V. (GLPG) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
5.71
5-year avg
5.71
10-year avg
5.71
Galapagos N.V.’s PE Ratio is greater than Arcus Biosciences, Inc. (-9.01), greater than Ocular Therapeutix, Inc. (-5.99), greater than ImmunityBio, Inc. (-7.59), greater than Viridian Therapeutics, Inc. (-5.97), greater than Cogent Biosciences, Inc. (-13.81), greater than Denali Therapeutics Inc. (-8.42), greater than uniQure N.V. (-10.88), greater than 89bio, Inc. (-12.37), greater than Structure Therapeutics Inc. (-18.99), greater than Mesoblast Limited (-20.41),
| Company | PE Ratio | Market cap |
|---|---|---|
| -9.01 | $3.59B | |
| -5.99 | $1.86B | |
| -7.59 | $7.74B | |
| -5.97 | $1.87B | |
| -13.81 | $7.27B | |
| -8.42 | $3.85B | |
| -10.88 | $3.05B | |
| -12.37 | $2.20B | |
| -18.99 | $2.89B | |
| -20.41 | $1.94B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galapagos N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Galapagos N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Galapagos N.V.'s PE Ratio?
How is the PE Ratio calculated for Galapagos N.V. (GLPG)?
What is the highest PE Ratio for Galapagos N.V. (GLPG)?
What is the 3-year average PE Ratio for Galapagos N.V. (GLPG)?
What is the 5-year average PE Ratio for Galapagos N.V. (GLPG)?
How does the current PE Ratio for Galapagos N.V. (GLPG) compare to its historical average?